Insiders Trades
Novartis AG Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest was filed 06 Mar 2026.
Novartis AG: what insiders have been doing
Headquartered in Basel, Switzerland, Novartis AG belongs to the Healthcare & Pharma sector and traces its origins to 1996. Filings by its managers are published through SIX SER. The last twelve months, up to 18 October 2026, brought 25 filings signed by 3 insiders.
Purchases and sales both appear in the filings: 5 purchases (2 insiders, €807k) and 20 sales (2 insiders, €37.5M). No amount is published for 5 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The filings include the largest sale, €10.4M, on 6 February 2026. Those buying include 2 senior executives.
With 25 filings in twelve months, the company is more active than the median of 9 filings across the 178 companies we follow on the same exchange. The full history, which starts in 2023, counts 15 purchases against 54 sales.
The most recent open-market purchase was published on 6 March 2026, 226 days ago. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SIX SER. Past trades are no guide to future returns.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€6M
15 ops. · all time
Sell Volume
€76M
54 ops. · all time
Who traded when
BuySaleAnonymous (Executive member of the board of directors / member of senior management)3 buys32 sales
Anonymous (an executive member of the board of directors / member of senior management)6 sales
Anonymous (Non-executive member of the board of directors)5 buys1 sale
Analyst consensus: bullish or bearish?
Analysts rate Novartis AG Hold (neutral), based on 22 analysts. Average price target: CHF 124.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,749 of 24,148 companies
72.6
score / 100
Value63
Quality82
FCF yld6.4%
Earn yld5.9%
EV/EBITDA11.9x
ROE30%
Gross mgn76%
Net mgn25%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 122.66
Analyst consensus
22 analystsHold
CHF 100.49Target CHF 124.60(+2%)CHF 149.86
Income statement
RevenueCHF 56.7B
Gross profitCHF 43B76% margin
EBITDACHF 22.8B40% margin
Net incomeCHF 14B22.5% margin
Valuation
PER (trailing)22.7x
PER (forward)12.5x
P/Book6.7x
Beta0.47
Balance sheet & cash
Market capCHF 233.1B
Total debtCHF 35.4B
Free Cash FlowCHF 15.2B
Debt / Equity117%
Profitability & ownership
ROE30.3%
ROA10.3%
% insiders2.1%
% institutions46.3%
Last declaration on 28 September 2026
Declarations69 total
▼
Anonymous (an executive member of the board of directors / member of senior management)
1,620 shares00.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q9S00091
1,620 shares@ CHF 0.00060.0% of flowISIN CH0012005267SIX:T1Q9S00091
90,389 shares00.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q9O00058
▼
Anonymous (an executive member of the board of directors / member of senior management)
3,131 shares00.0000% mcap0.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q9O00066
3,131 shares@ CHF 0.00030.0% of flowISIN CH0012005267SIX:T1Q9O00066
90,389 shares0.0% of flowISIN CH0012005267SIX:T1Q9O00058
▼
Anonymous (an executive member of the board of directors / member of senior management)
10,000 shares@ CHF 129.000.0006% mcap49.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q7R00030
▼
Anonymous (an executive member of the board of directors / member of senior management)
5,200 shares@ CHF 117.5019.9% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5I00074
▼
Anonymous (Executive member of the board of directors / member of senior management)
5,200 shares@ CHF 117.5040.7% of flowISIN CH0012005267SIX:T1Q5I00074
▼
Anonymous (an executive member of the board of directors / member of senior management)
6,800 shares@ CHF 117.1630.9% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U000D3
▼
Anonymous (Executive member of the board of directors / member of senior management)
6,800 shares@ CHF 117.15611.1% of flowISIN US66987V1098SIX:T1Q4U000D3
1 shares@ CHF 380,000.0032.3% of flowISIN CH0012005267SIX:T1Q3600095
Canonical exit: 4 Jun 2026 (T+90)
1 shares0ISIN CH0012005267SIX:T1Q36000C1
Canonical exit: 4 Jun 2026 (T+90)
1 shares0ISIN CH0012005267SIX:T1Q36000B3
Canonical exit: 4 Jun 2026 (T+90)
1 shares0ISIN CH0012005267SIX:T1Q36000A5
Canonical exit: 4 Jun 2026 (T+90)
30,743 shares@ CHF 124.3745.4% of flowISIN US66987V1098SIX:T1Q2C00058
▼
Anonymous (Executive member of the board of directors / member of senior management)
7,500 shares@ CHF 120.76471.3% of flowISIN US66987V1098SIX:T1Q2900033
80,326 shares@ CHF 118.914313.5% of flowISIN CH0012005267SIX:T1Q2600054
30,160 shares@ CHF 119.22035.1% of flowISIN CH0012005267SIX:T1Q2600062
67,000 shares@ CHF 117.39311.1% of flowISIN CH0012005267SIX:T1Q2500098
21,256 shares@ CHF 117.89593.5% of flowISIN CH0012005267SIX:T1Q2500049
▲
Anonymous (Executive member of the board of directors / member of senior management)
3,112 shares@ CHF 114.200.5% of flowISIN CH0012005267SIX:T1Q1S00015
Canonical exit: 28 Apr 2026 (T+90)
5,933 shares@ CHF 0.00020.0% of flowISIN CH0012005267SIX:T1PBD00069
20,000 shares@ CHF 101.71772.8% of flowISIN CH0012005267SIX:T1PB7000B9
▼
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 98.52750.3% of flowISIN CH0012005267SIX:T1PAU00081
25 of 69 declarations
About Novartis AG
Novartis AG is one of the world’s leading innovative medicines companies and a core blue-chip name on the Swiss market, listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. The group was formed in 1996 through the merger of Ciba-Geigy and Sandoz, and it remains headquartered in Basel, the historic center of its scientific and corporate identity. That Swiss origin still matters: Novartis combines a strong domestic base with a genuinely global operating footprint.
The company’s business model is centered on discovering, developing, manufacturing, and commercializing prescription medicines with high medical value. Novartis focuses on major therapeutic areas where unmet need remains significant, notably oncology, immunology, cardiovascular, renal and metabolic diseases, and neuroscience. Beyond therapeutic franchises, the group has built technology capabilities in small molecules, biologics, xRNA, radioligand therapy, and gene and cell therapy. This gives Novartis a differentiated innovation platform and supports a portfolio that is less dependent on any single product cycle.
Read moreShow less
Its commercial portfolio includes several well-known brands, such as Cosentyx in immune-mediated inflammatory diseases, Entresto in cardiology, Kisqali in oncology, Xolair in allergy and immunology, Leqvio for LDL-cholesterol reduction, Fabhalta in selected kidney diseases, and Pluvicto in radioligand therapy. More recently, the company has added or expanded newer assets such as Rhapsido and Itvisma. From an equity research perspective, this mix of established blockbusters and pipeline-driven launches is central to the investment case, because it supports both cash generation and medium-term growth optionality.
Geographically, Novartis sells its medicines in more than 100 countries and operates a broad network spanning research, manufacturing, and distribution. The United States is a major commercial market, but Switzerland remains strategically important for governance, R&D, and corporate heritage. Recent corporate and regulatory news has been supportive: in 2025 Novartis secured FDA approvals for Rhapsido, Vanrafia, Pluvicto in an earlier treatment setting, and Itvisma, while also expanding the label for Leqvio. The company also agreed to acquire Anthos Therapeutics to strengthen its late-stage cardiovascular pipeline. For international investors, Novartis stands out as a large-cap healthcare compounder with a defensive earnings profile, a deep innovation pipeline, and a prominent listing on the SIX Swiss Exchange (SMI/SPI) in Switzerland.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
